AzTrials
AzTrials

Vascular Access Site ComplicationGLUE-EPNCT07926191

Tissue Adhesive Versus Figure-of-Eight Suture for Femoral Venous Closure After Electrophysiology Procedures (GLUE-EP)

An observational study of Vascular Access Site Complication and Hematoma, run by Nemocnice AGEL Trinec-Podlesi a.s. at 1 site in Czechia.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

In July 2026 the electrophysiology laboratory of a Czech tertiary cardiology centre introduced topical cyanoacrylate tissue adhesive (DERMABOND Mini or Histoacryl) as a routine alternative to the figure-of-eight suture for closing femoral venous puncture sites after electrophysiology procedures, including pulsed-field… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Topical cyanoacrylate tissue adhesive and Figure-of-eight suture
How many people
1,400 participants
Where
1 siteCzechia
Study dates
Dec 2026to Sep 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults undergoing elective electrophysiology procedures (diagnostic EP studies and catheter ablations, including pulsed-field ablation) with femoral venous access at the electrophysiology laboratory of Nemocnice AGEL Trinec-Podlesi a.s., Czechia, identified consecutively from the departmental procedure registry within the defined periods.

Who may be able to join

  • Age 18 years or older
  • Elective electrophysiology procedure (diagnostic study or catheter ablation) with at least one femoral venous sheath
  • Femoral venous puncture site closed with topical cyanoacrylate tissue adhesive (Groups A and P) or with a figure-of-eight suture (Groups B and C)
  • Group P only: written informed consent to the use of routine medical records

Who cannot join

  • Arterial access during the same procedure
  • Non-elective or emergency procedure
  • Groups B and C: documentation of a closure method other than a figure-of-eight suture (compression alone, vascular closure device)
  • Group P only: inability to understand the patient information or to give consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Otakar Jiravsky, MUDr., Ph.D., MBA contact

+420 602 579 193

otakar.jiravsky@npo.agel.cz

Jan Chovancik, MUDr., Ph.D., MBA contact

+420 558 304 111

jan.chovancik@npo.agel.cz

Czechia1 site
  • Nemocnice AGEL Trinec-Podlesi a.s.

    Třinec, 73961

    Otakar Jiravsky, MUDr., Ph.D., MBA, +420 602 579 193, otakar.jiravsky@npo.agel.cz

    Otakar Jiravsky, MUDr., Ph.D., MBA

Other trials in Czechia

About this study

Official title: Topical Cyanoacrylate Tissue Adhesive Versus Figure-of-Eight Suture for Closure of Femoral Venous Access After Electrophysiology Procedures, Including Large-Bore Pulsed-Field Ablation: a Single-Centre Retrospective Cohort Study With Prospective Continuation (GLUE-EP)

In July 2026 the electrophysiology laboratory of a Czech tertiary cardiology centre introduced topical cyanoacrylate tissue adhesive (DERMABOND Mini or Histoacryl) as a routine alternative to the figure-of-eight suture for closing femoral venous puncture sites after electrophysiology procedures, including pulsed-field ablation performed through 13-17 F sheaths. After sheath removal, haemostasis is achieved by manual compression and the adhesive seals the skin over the puncture. The change was a clinical decision of the department, not a study intervention.

Published experience with this approach is limited, particularly for large-bore venous sheaths. GLUE-EP evaluates the access-site safety of the practice change using routinely recorded data only. Procedures closed with tissue adhesive are compared with a historical cohort closed with a figure-of-eight suture in 2024-2025 (propensity-score matched) and with a concurrent cohort closed with a suture during the same period. A prospective continuation collects the same routine data until 30 June 2027 from patients who give written informed consent.

The study assigns no treatment, adds no examination, questionnaire or study visit, and does not influence how the puncture site is closed. The primary outcome is any major or minor access-site vascular complication within 30 days of the procedure.

Read the detailed description

BACKGROUND

Closure of the femoral venous puncture site is the most frequent source of complications after electrophysiology (EP) procedures. The departmental standard has been a percutaneous figure-of-eight suture, removed 2 to 6 hours after the procedure. Topical cyanoacrylate tissue adhesive is an alternative that requires no removal: after sheath removal, haemostasis is achieved by manual compression and the adhesive then seals the skin over the puncture, which is the use for which the CE-marked products are intended. With the spread of pulsed-field ablation, venous sheath size has increased to 13-17 F, so the question of closure is most pressing for large-bore access. Published experience is limited: the only comparative report identified in PubMed concerns skin adhesive combined with a vascular closure device after atrial fibrillation ablation, not adhesive used instead of a suture.

PRACTICE CHANGE

Since 1 July 2026 the EP laboratory of Nemocnice AGEL Trinec-Podlesi a.s. (Czechia) has used topical cyanoacrylate tissue adhesive (2-octyl cyanoacrylate, DERMABOND Mini; or n-butyl-2-cyanoacrylate, Histoacryl) as a standard alternative to the figure-of-eight suture. This was a clinical decision of the department, not a research intervention. By 17 September 2026, 192 procedures had been closed with adhesive (177 catheter ablations and 15 diagnostic EP studies; 127 pulsed-field ablations through 13-17 F sheaths). Adhesive was used in 40%, 73% and 72% of procedures in July, August and September 2026, respectively.

DESIGN

Single-centre observational cohort study in two parts with identical population and outcome definitions. The study does not assign the closure method; it is chosen by the treating physician.

Part R (retrospective):

  • Group A: procedures closed with adhesive from 1 July 2026 to the date of the ethics committee opinion (data cut-off 30 September 2026 for the first analysis).
  • Group B: procedures closed with a figure-of-eight suture from 1 January 2024 to 31 December 2025 (historical comparator).
  • Group C: procedures of the same period as Group A closed with a figure-of-eight suture (concurrent comparator).

Part P (prospective continuation): procedures closed with adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Consent is sought at admission from all patients scheduled for an elective EP procedure with femoral venous access, because the closure method is decided during the procedure; only patients whose puncture site is closed with adhesive enter the analysis. The same routine variables are collected from the same sources; apart from obtaining consent, there is no additional examination, measurement, questionnaire or patient contact.

ASCERTAINMENT OF THE CLOSURE METHOD

In 2026, adhesive use is recorded in the departmental procedure registry. For Groups B and C, the closure method is taken from the procedure report and discharge summary. Because the figure-of-eight suture was the departmental standard, a procedure is classified as suture-closed unless another method is documented; procedures with another documented method (compression alone, vascular closure device) are excluded. The proportion of procedures without an explicit record of the suture is reported, and a sensitivity analysis restricts Groups B and C to procedures with an explicit record.

ASCERTAINMENT OF OUTCOMES

Access-site complications are identified from discharge summaries and from all records in the hospital information system up to day 30 after the procedure (outpatient visits, emergency department visits, readmissions, telephone contacts), not from the complication field of the departmental registry. A procedure without any record after discharge is counted as having no recorded complication; the proportion of such procedures is reported by group, and these procedures are excluded in a sensitivity analysis.

STATISTICAL ANALYSIS

Groups A and B are matched 1:1 by propensity score (nearest neighbour without replacement, caliper 0.2 SD of the logit of the score, exact matching on sheath size 5-9 F versus 13-17 F). The score is estimated by logistic regression from age, sex, procedure type, ablation system, number and size of sheaths, antithrombotic therapy and ultrasound-guided puncture; balance is checked by standardised differences (target below 0.1). The primary comparison (Group A versus matched Group B) uses the McNemar test and conditional logistic regression (odds ratio with 95% confidence interval). The comparison with Group C uses covariate-adjusted logistic regression, with inverse probability weighting as a sensitivity analysis. Binary secondary outcomes are analysed by logistic regression and length of stay (nights) by negative binomial regression. Part P is analysed descriptively and compared with Group A, with complication and conversion rates shown by calendar quarter. The large-bore (13-17 F) subgroup is pre-specified and analysed descriptively.

There is no formal sample size calculation; all eligible procedures in the defined periods are included. The study is estimation-oriented and is not designed to demonstrate non-inferiority. With 192 adhesive procedures, 0, 2 and 4 observed events correspond to upper limits of the 95% Wilson confidence interval of 2.0%, 3.7% and 5.2%, respectively.

Not collected: time to haemostasis, time to ambulation, pain scores, patient satisfaction, closure cost and operator confidence. These are not recorded in routine documentation and will not be reported.

ETHICS AND DATA PROTECTION

The protocol was submitted to the Ethics Committee of Nemocnice AGEL Trinec-Podlesi a.s. in October 2026, with a request for waiver of informed consent for Groups A, B and C; written informed consent is obtained in Part P. The analytic dataset is pseudonymised; the key is held on a secure hospital server and is accessible only to the principal investigator. Only aggregate data are reported.

DISSEMINATION

Abstract at an international cardiology congress and publication in a peer-reviewed journal regardless of the direction of the results.

Being tested
Topical cyanoacrylate tissue adhesive, Figure-of-eight suture
Keywords
cyanoacrylate, tissue adhesive, DERMABOND, Histoacryl, femoral venous access, figure-of-eight suture, vascular access closure, electrophysiology, catheter ablation, pulsed-field ablation, large-bore venous access, same-day discharge
Medical subject headings
Hematoma, Atrial Fibrillation, Arrhythmias, Cardiac

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Topical cyanoacrylate tissue adhesiveDevice

    Also called DERMABOND Mini, Histoacryl

    Routine clinical practice, not assigned by the study. After sheath removal and haemostasis by manual compression, the skin over the femoral venous puncture is sealed with CE-marked topical cyanoacrylate tissue adhesive: 2-octyl cyanoacrylate (DERMABOND Mini) or n-butyl-2-cyanoacrylate (Histoacryl).

  • Figure-of-eight sutureProcedure or surgery

    Routine clinical practice, not assigned by the study. Percutaneous figure-of-eight (purse-string) skin suture placed over the femoral venous puncture after sheath removal and released 2 to 6 hours later.

Study groups in NCT07926191
Study groupRoleWhat they receive
Group A: Tissue adhesive (retrospective)Elective EP procedures with femoral venous puncture sites closed with topical cyanoacrylate tissue adhesive from 1 July 2026 to the date of the ethics committee opinion. Data from routine records; waiver of consent requested.
Receives: Device: Topical cyanoacrylate tissue adhesive
Group B: Figure-of-eight suture (historical)Elective EP procedures closed with a percutaneous figure-of-eight suture from 1 January 2024 to 31 December 2025; propensity-score matched 1:1 to Group A. Data from routine records; waiver of consent requested.
Receives: Procedure: Figure-of-eight suture
Group C: Figure-of-eight suture (concurrent)Elective EP procedures of the same period as Group A (from 1 July 2026 to the date of the ethics committee opinion) in which adhesive was not used and the puncture site was closed with a figure-of-eight suture. Data from routine records; waiver of consent requested.
Receives: Procedure: Figure-of-eight suture
Group P: Tissue adhesive (prospective continuation)Elective EP procedures closed with topical cyanoacrylate tissue adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Same routine variables and sources as Group A.
Receives: Device: Topical cyanoacrylate tissue adhesive

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Access-Site Vascular Complications

    Any major or minor vascular complication at the femoral venous access site, using VARC-3 criteria adapted for venous access. Major: bleeding requiring transfusion or surgical or interventional revision; pseudoaneurysm or arteriovenous fistula requiring treatment; access-site infection requiring systemic antibiotics or revision; deep vein thrombosis. Minor: haematoma without transfusion or revision but with prolonged hospital stay or unplanned healthcare contact; pseudoaneurysm or fistula managed conservatively; local reaction requiring treatment. Ascertained from discharge summaries and all hospital records up to day 30. Primary comparison: Group A versus propensity-matched Group B; key secondary comparison: Group A versus Group C. Pre-specified subgroup: 13-17 F sheaths.

    Measured: From the procedure through 30 days after the procedure

Secondary outcomes (4)
  1. Number of Participants Requiring Conversion From Tissue Adhesive to Figure-of-Eight Suture

    Conversion to a figure-of-eight suture because of inadequate haemostasis immediately after sheath removal, in procedures intended for adhesive closure (Groups A and P). Ascertained from the procedure report and discharge summary.

    Measured: During the index procedure (day 0)

  2. Number of Participants Discharged on the Day of the Procedure

    Discharge from hospital on the calendar day of the index procedure, as recorded in the departmental registry.

    Measured: Day 0 (day of the procedure)

  3. Length of Post-Procedural Hospital Stay

    Number of nights spent in hospital after the index procedure, taken from the discharge summary.

    Measured: From the procedure to hospital discharge, assessed up to 30 days

  4. Number of Participants With Unplanned Healthcare Contact Related to the Access Site

    Any unplanned outpatient visit, emergency department visit, readmission or telephone contact related to the femoral access site, as recorded in the hospital information system.

    Measured: From discharge through 30 days after the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2026
  2. Study startDec 2026 (estimated)
  3. Primary completionJul 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
1,400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07926191
Sponsor's protocol ID
GLUE-EP-2026-01
Acronym
GLUE-EP
Status last verified
Oct 2026
First submitted
3 Nov 2026
Last updated
9 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Only aggregate results will be published. Individual participant data will not be shared: the retrospective part relies on a waiver of consent, and participants in the prospective part consent to the use of their pseudonymised data by the study team only.

Publications

  • Takada Y, Kamoshida J, Terasawa M, Satomi K, Yazaki Y. Combination of Skin Adhesives and Vascular Closure Device for Complete Hemostasis After Catheter Ablation. Circ Rep. 2026 Apr 29;8(6):869-877. doi: 10.1253/circrep.CR-25-0288. eCollection 2026 Jun 10.

    PubMed 42273310
  • VARC-3 WRITING COMMITTEE:; Genereux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746. doi: 10.1016/j.jacc.2021.02.038. Epub 2021 Apr 19.

    PubMed 33888385

Questions about this trial

What is this clinical trial studying?

An observational study of Vascular Access Site Complication and Hematoma, run by Nemocnice AGEL Trinec-Podlesi a.s. at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Otakar Jiravsky, MUDr., Ph.D., MBA (+420 602 579 193, otakar.jiravsky@npo.agel.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Access-Site Vascular Complications (time frame: From the procedure through 30 days after the procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07926191, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in